Affinity Biologicals Inc. Utilizes Bethesda Assay in the Quantification of Inhibitors that Develop Against Coagulation Factors

Affinity Biologicals Inc. Utilizes Bethesda Assay in the Quantification of Inhibitors that Develop Against Coagulation Factors

Ancaster, ON – Hemophilia A is a bleeding disorder in which individuals lack the factor VIII necessary for their bodies to properly clot blood. Affinity Biologicals Inc. scientists utilize the Bethesda assay to determine and monitor the concentration of the factor VIII inhibitor.

At Affinity Biologicals Inc. the Bethesda assay is commonly used by researchers who are monitoring the potency of inhibitors in frozen and lyophilized plasmas. According to Affinity, “FIPs are an economical and reliable alternative to human clinical source material that can be very difficult to obtain. Even samples from extremely rare conditions can be emulated in this way. FIPs are available in volumes ranging from 1 mL vials up to bulk volumes.”

In order to ensure that Factor Inhibitor Plasmas are more available for individuals, Affinity Biologicals Inc. uses the Bethesda assay in their research. To learn more about the Bethesda assay and its applications visit the Affinity Biologicals Inc. website at https://affinitybiologicals.com/.

About Affinity Biologicals Inc.

Affinity Biologicals is a renowned name associated with the medical research and diagnostics industry since 1987. The company has manufactured over 250 reagents used internationally in the research and diagnostics of hemostasis and thrombosis to date. The product range of Affinity Biologicals include coagulation antibodies, deficient plasmas, antibody sets of ELISA, control plasmas, custom plasmas, and factor inhibitor plasmas.